Evidence map›Paper›PMID 36077316›Full record

ArticleInternational journal of molecular sciences2022

Topical Administration of a Marine Oil Rich in Pro-Resolving Lipid Mediators Accelerates Wound Healing in Diabetic

Imelda Ontoria-Oviedo, Elena Amaro-Prellezo, Delia Castellano, Elena Venegas-Venegas, Fernando González-Santos, Amparo Ruiz-Saurí, Beatriz Pelacho, Felipe Prósper, María Dolores Pérez Del Caz, Pilar Sepúlveda

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Imelda Ontoria-OviedoRegenerative Medicine and Heart Transplantation Unit, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain.ORCID 0000-0002-2497-1325
Elena Amaro-PrellezoRegenerative Medicine and Heart Transplantation Unit, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain.
Delia CastellanoRegenerative Medicine and Heart Transplantation Unit, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain.
Elena Venegas-VenegasSolutex GC, S.L., Parque Empresarial Utebo, 50180 Utebo, Spain.
Fernando González-SantosSolutex GC, S.L., Parque Empresarial Utebo, 50180 Utebo, Spain.
Amparo Ruiz-SauríDepartamento de Patología, Facultad de Medicina, Instituto de Investigación Sanitaria INCLIVA, Universitat de Valencia, 46026 Valencia, Spain.ORCID 0000-0001-7953-6577
Beatriz PelachoRegenerative Medicine Department, Center for Applied Medical Research (CIMA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-0411-7164
Felipe PrósperRegenerative Medicine Department, Center for Applied Medical Research (CIMA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0001-6115-8790
María Dolores Pérez Del CazRegenerative Medicine and Heart Transplantation Unit, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain.
Pilar SepúlvedaRegenerative Medicine and Heart Transplantation Unit, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain.
Instituto de Investigación Sanitaria La Fe · ESNavarre Institute of Health Research · ESInstituto de Salud Carlos III · ESUniversitat de València · ES

Funding

Generalitat Valenciana ACIF/2020/352Ministry of Economy, Industry and Competitiveness PROJECT RESOLTEX (RTC-2015-4185-1)nstituto de Salud Carlos III (ISCIII) and co-funded by European Regional Development Fund-FEDER PI19/00245 and PI19/00501RETICS Program RD16/0011/0004 and RD16/0011/0005
6 · The paper itself

Abstract

Impaired wound healing in patients with type 2 diabetes (DM2) is characterized by chronic inflammation, which delays wound closure. Specialized pro-resolving lipid mediators (SPMs) are bioactive molecules produced from essential polyunsaturated fatty acids (PUFAs), principally omega-3 docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). SPMs are potent regulators of inflammation and have been used to suppress chronic inflammation in peripheral artery disease, non-alcoholic fatty liver disease, and central nervous system syndromes. LIPINOVA

Indexed as

Diabetes Mellitus, Type 2Fatty Acids, Omega-3Administration, TopicalAnimalsDocosahexaenoic AcidsEicosapentaenoic AcidInflammationMacrophagesMiceWound HealingDocosahexaenoic AcidsEicosapentaenoic AcidFatty Acids, Omega-3angiogenesisdiabetic ulcermacrophage polarizationomega-3pro-resolving lipid mediatorsSPMswound healing

Identifiers

PMID36077316
PMCPMC9456080
OpenAlexW4294307496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.